SynthesisBMC infectious diseases2025
Significant histologic alterations in untreated chronic hepatitis B children: a meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 logJournal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChronic hepatitis B (CHB) in children poses a significant public health challenge, yet data on the prevalence of significant liver lesions in this group are limited.
methodsA comprehensive meta-analysis pooled data on the proportion of significant liver lesions among CHB children. Using the double arcsine transformation and a random-effects model, we combined data on moderate to severe liver inflammation, fibrosis, and cirrhosis. Subgroup analysis and meta-regression were conducted to explore heterogeneity.
resultsTwenty-two studies with 3,037 participants were included. The proportion of moderate to severe inflammation was 41.54% [95% Confidence Interval (CI): 29.14-54.47%], notable fibrosis was 31.71% [95% CI: 23.85-40.11%], and cirrhosis was 2.27% [95% CI: 1.06-3.82%]. Inflammation varied significantly by age group: < 6 years, 36.21%; 6-12 years, 53.72%; 12-18 years, 31.40% (p < 0.01). ALT ≥ 80 U/L was associated with higher inflammation (57.78%) compared to ALT < 80 U/L (29.73%) (p < 0.01). Cirrhosis also varied significantly by age group.
conclusionsA substantial proportion of CHB children have significant liver lesions, underscoring the need for enhanced screening and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.